We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+56.41%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$281M
AUM Growth
+$70.9M
Cap. Flow
+$19.6M
Cap. Flow %
6.97%
Top 10 Hldgs %
63.76%
Holding
43
New
10
Increased
13
Reduced
5
Closed
13

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$8.77M
2
MIST icon
Milestone Pharmaceuticals
MIST
+$7.16M
3
ARWR icon
Arrowhead Research
ARWR
+$6.83M
4
ATNX
Athenex, Inc. Common Stock
ATNX
+$6.55M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$5.96M

Top Sells

Rank Stock Value
1
CASM
CAS Medical Systems, Inc.
CASM
+$12.8M
2
ASMB icon
Assembly Biosciences
ASMB
+$9.54M
3
DERM
Dermira, Inc.
DERM
+$8.63M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$7.79M
5
CBAY
Cymabay Therapeutics
CBAY
+$6.87M

Sector Composition

Rank Sector Weight
1 Healthcare 86.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOVA icon
1
Iovance Biotherapeutics
IOVA
$1.93B
$59.5M 21.16%
2,426,701
-517,500
-18% -$7.79M
XBI icon
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
$17.5M 6.24%
+200,000
New +$17.1M
KDMN
3
DELISTED
Kadmon Holdings, Inc.
KDMN
$15.7M 5.58%
7,617,500
-17,500
-0.2% -$39K
ADVM
4
DELISTED
Adverum Biotechnologies
ADVM
$14.1M 5.03%
119,000
+27,100
+29% +$2.24M
VCYT icon
5
Veracyte
VCYT
$3.58B
$13.7M 4.88%
481,500
+100,000
+26% +$2.5M
ARWR icon
6
Arrowhead Research
ARWR
$12.1B
$12.7M 4.51%
478,500
+311,000
+186% +$6.83M
ARVN icon
7
Arvinas
ARVN
$520M
$12.1M 4.31%
551,000
+237,000
+75% +$4.98M
ARGX icon
8
argenx
ARGX
$52B
$11.5M 4.08%
81,000
+17,500
+28% +$2.22M
AXSM icon
9
Axsome Therapeutics
AXSM
$10.9B
$11.3M 4.01%
+437,500
New +$8.77M
BHVN
10
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$11.2M 3.97%
255,000
+49,000
+24% +$2.76M
INSM icon
11
Insmed
INSM
$21.3B
$11.1M 3.96%
435,500
+65,500
+18% +$1.82M
MIST icon
12
Milestone Pharmaceuticals
MIST
$139M
$9.42M 3.35%
+347,000
New +$7.16M
ATNX
13
DELISTED
Athenex, Inc. Common Stock
ATNX
$9.36M 3.33%
+23,625
New +$6.55M
PTGX icon
14
Protagonist Therapeutics
PTGX
$8.51B
$8.13M 2.89%
671,500
+334,000
+99% +$3.69M
VRAY
15
DELISTED
ViewRay, Inc.
VRAY
$7.42M 2.64%
842,500
+27,500
+3% +$223K
XENE icon
16
Xenon Pharmaceuticals
XENE
$6.02B
$6.92M 2.46%
701,500
+149,000
+27% +$1.43M
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$6.44M 2.29%
62,500
+21,500
+52% +$1.67M
AUPH icon
18
Aurinia Pharmaceuticals
AUPH
$1.87B
$6.15M 2.19%
+935,000
New +$5.96M
DRNA
19
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$6.06M 2.15%
384,500
+55,675
+17% +$757K
IRIX icon
20
IRIDEX
IRIX
$14.4M
$5.33M 1.89%
1,171,300
-3,200
-0.3% -$15.6K
KALV
21
DELISTED
KalVista Pharmaceuticals
KALV
$4.72M 1.68%
213,000
+7,500
+4% +$176K
FOLD
22
DELISTED
Amicus Therapeutics
FOLD
$4.37M 1.55%
+350,000
New +$4.44M
CRSP icon
23
CRISPR Therapeutics
CRSP
$4.88B
$3.72M 1.32%
+79,000
New +$3.16M
IMMU
24
DELISTED
Immunomedics Inc
IMMU
$3.12M 1.11%
225,000
-275,000
-55% -$4.14M
BHVN
25
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$2.19M 0.78%
50,000
– –
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2019 Portfolio in Review

As of Q2 2019, Acuta Capital Partners held 43 positions worth $281M, up 34% from $210M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Acuta Capital Partners deployed $19.6M of net new capital in Q2 2019, opening 10 new positions and adding to 13 existing holdings. Its largest new stake was Axsome Therapeutics: 437,500 shares worth $11.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier.

On the sell side, the largest reduction was Assembly Biosciences, an estimated $9.54M trimmed.

  • Acuta Capital Partners's largest Q2 2019 buy was Axsome Therapeutics: 437,500 shares worth $11.3M.
  • Acuta Capital Partners added most to Arrowhead Research in Q2 2019, an estimated $6.83M increase.
  • Acuta Capital Partners's biggest Q2 2019 reduction was Assembly Biosciences, cutting an estimated $9.54M.
  • Acuta Capital Partners fully exited CAS Medical Systems, Inc. in Q2 2019, selling an estimated $12.8M.
  • Acuta Capital Partners's ten largest holdings make up 64% of its $281M portfolio in Q2 2019.
  • Acuta Capital Partners opened 10 new positions and closed 13 in Q2 2019.
  • Acuta Capital Partners's portfolio value rose 34% quarter-over-quarter to $281M.

Based on Acuta Capital Partners's 13F filing for Q2 2019, filed 14 Aug 2019.